Statins decrease chondroitin sulfate proteoglycan expression and acute astrocyte activation in central nervous system injury

Experimental Neurology

Volumn 214, Issue 1, 2008, Pages 78-86

  Holmberg, Eric ^a,b   Zhang, Shu xin ^a   Sarmiere, Patrick D ^a   Kluge, Bridget R ^a   White, Jason T ^a   Doolen, Suzanne ^a  

^a Spinal Cord Society Research Center   (United States)

^b UNIVERSITY OF ALASKA ANCHORAGE   (United States)

Author keywords

Chondroitin sulfate proteoglycan; GFAP; RhoA; Spinal cord injury; Statins

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; PROTEOCHONDROITIN SULFATE; SIMVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN LEVEL; CELL ACTIVATION; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IMMUNOREACTIVITY; LOCOMOTION; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPINAL CORD INJURY;

ANIMALS; ASTROCYTES; BLOTTING, WESTERN; BRAIN INJURIES; CELLS, CULTURED; CEREBRAL CORTEX; GLIAL FIBRILLARY ACIDIC PROTEIN; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; MALE; MOTOR ACTIVITY; NERVE REGENERATION; PROTEOCHONDROITIN SULFATES; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIMVASTATIN; SPINAL CORD INJURIES;

EID: 53949101802     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2008.07.020     Document Type: Article

References (53)

1. Abe K., and Misawa M. Astrocyte stellation induced by Rho kinase inhibitors in culture. Brain Res. Dev. Brain Res. 143 (2003) 99-104
2. Alabed Y.Z., Grados-Munro E., Ferraro G.B., Hsieh S.H., and Fournier A.E. Neuronal responses to myelin are mediated by rho kinase. J. Neurochem. 96 (2006) 1616-1625
3. Ambrosini E., and Aloisi F. Chemokines and glial cells: a complex network in the central nervous system. Neurochem. Res. 29 (2004) 1017-1038
4. Andrews T.C., Ballantyne C.M., Hsia J.A., and Kramer J.H. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am. J. Med. 111 (2001) 185-191
5. Basso D.M., Beattie M.S., and Bresnahan J.C. A sensitive and reliable locomotor rating scale for open field testing in rats. J. Neurotrauma 12 (1995) 1-21
6. Basso D.M., Beattie M.S., and Bresnahan J.C. Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Exp. Neurol. 139 (1996) 244-256
7. Bonetti P.O., Lerman L.O., Napoli C., and Lerman A. Statin effects beyond lipid lowering-are they clinically relevant?. Eur. Heart. J. 24 (2003) 225-248
8. Chan C.C., Wong A.K., Liu J., Steeves J.D., and Tetzlaff W. ROCK inhibition with Y27632 activates astrocytes and increases their expression of neurite growth-inhibitory chondroitin sulfate proteoglycans. Glia 55 (2007) 369-384
9. Chu G., Jia R., and Yang D. Fluvastatin prevents oxidized low-density lipoprotein-induced injury of renal tubular epithelial cells by inhibiting the phosphatidylinositol 3-kinase/Akt-signaling pathway. J. Nephrol. 19 (2006) 286-295
10. Constantini S., and Young W. The effects of methylprednisolone and the ganglioside GM1 on acute spinal cord injury in rats. J. Neurosurg. 80 (1994) 97-111
11. Daub K., Langer H., Seizer P., Stellos K., May A.E., Goyal P., Bigalke B., Schonberger T., Geisler T., Siegel-Axel D., Oostendorp R.A., Lindemann S., and Gawaz M. Platelets induce differentiation of human CD34+ progenitor cells into foam cells and endothelial cells. FASEB J. 20 (2006) 2559-2561
12. Davidson M.H., Stein E.A., Dujovne C.A., Hunninghake D.B., Weiss S.R., Knopp R.H., Illingworth D.R., Mitchel Y.B., Melino M.R., Zupkis R.V., Dobrinska M.R., Amin R.D., and Tobert J.A. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am. J. Cardiol. 79 (1997) 38-42
13. Davies S.J., Fitch M.T., Memberg S.P., Hall A.K., Raisman G., and Silver J. Regeneration of adult axons in white matter tracts of the central nervous system. Nature 390 (1997) 680-683
14. Davies S.J., Goucher D.R., Doller C., and Silver J. Robust regeneration of adult sensory axons in degenerating white matter of the adult rat spinal cord. J. Neurosci. 19 (1999) 5810-5822
15. Dergham P., Ellezam B., Essagian C., Avedissian H., Lubell W.D., and McKerracher L. Rho signaling pathway targeted to promote spinal cord repair. J. Neurosci. 22 (2002) 6570-6577
16. Dubreuil C.I., Winton M.J., and McKerracher L. Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J. Cell. Biol. 162 (2003) 233-243
17. Fawcett J.W., and Asher R.A. The glial scar and central nervous system repair. Brain Res. Bull. 49 (1999) 377-391
18. Hatten M.E. Neuronal regulation of astroglial morphology and proliferation in vitro. J. Cell. Biol. 100 (1985) 384-396
19. Holmberg E., Nordstrom T., Gross M., Kluge B., Zhang S.X., and Doolen S. Simvastatin promotes neurite outgrowth in the presence of inhibitory molecules found in central nervous system injury. J. Neurotrauma 23 (2006) 1366-1378
20. Iaci J.F., Vecchione A.M., Zimber M.P., and Caggiano A.O. Chondroitin sulfate proteoglycans in spinal cord contusion injury and the effects of chondroitinase treatment. J. Neurotrauma 24 (2007) 1743-1759
21. Jin Z., and Strittmatter S.M. Rac1 mediates collapsin-1-induced growth cone collapse. J. Neurosci. 17 (1997) 6256-6263
22. Kusama T., Mukai M., Iwasaki T., Tatsuta M., Matsumoto Y., Akedo H., and Nakamura H. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res. 61 (2001) 4885-4891
23. Laufs U., and Liao J.K. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc. Med. 10 (2000) 143-148
24. Laufs U., and Liao J.K. Isoprenoid metabolism and the pleiotropic effects of statins. Curr. Atheroscler. Rep. 5 (2003) 372-378
25. Lee C.Y., Pappas G.D., Kriho V., Huang B.M., and Yang H.Y. Proliferation of a subpopulation of reactive astrocytes following needle-insertion lesion in rat. Neurol. Res. 25 (2003) 767-776
26. Leonard S., Beck L., and Sinensky M. Inhibition of isoprenoid biosynthesis and the post-translational modification of pro-p21. J. Biol. Chem. 265 (1990) 5157-5160
27. Mantha A.J., Hanson J.E., Goss G., Lagarde A.E., Lorimer I.A., and Dimitroulakos J. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin. Cancer Res. 11 (2005) 2398-2407
28. Martin J., Denver R., Bailey M., and Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clin. Exp. Pharmacol. Physiol. 32 (2005) 697-701
29. Marz P., Otten U., and Miserez A.R. Statins induce differentiation and cell death in neurons and astroglia. Glia 55 (2007) 1-12
30. McCarey D.W., McInnes I.B., Madhok R., Hampson R., Scherbakov O., Ford I., Capell H.A., and Sattar N. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363 (2004) 2015-2021
31. McGillicuddy F.C., O'Toole D., Hickey J.A., Gallagher W.M., Dawson K.A., and Keenan A.K. TGF-beta1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells. Vasc. Pharmacol. 44 (2006) 469-475
32. McKeon R.J., Schreiber R.C., Rudge J.S., and Silver J. Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes. J. Neurosci. 11 (1991) 3398-3411
33. McKerracher L., David S., Jackson D.L., Kottis V., Dunn R.J., and Braun P.E. Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron 13 (1994) 805-811
34. McKerracher L., and Winton M.J. Nogo on the go. Neuron 36 (2002) 345-348
35. Mukhopadhyay G., Doherty P., Walsh F.S., Crocker P.R., and Filbin M.T. A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron 13 (1994) 757-767
36. Neumann S., Bradke F., Tessier-Lavigne M., and Basbaum A.I. Regeneration of sensory axons within the injured spinal cord induced by intraganglionic cAMP elevation. Neuron 34 (2002) 885-893
37. Neumann S., Skinner K., and Basbaum A.I. Sustaining intrinsic growth capacity of adult neurons promotes spinal cord regeneration. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 16848-16852
38. Pannu R., Barbosa E., Singh A.K., and Singh I. Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats. J. Neurosci. Res. 79 (2005) 340-350
39. Pannu R., Christie D.K., Barbosa E., Singh I., and Singh A.K. Post-trauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury. J. Neurochem. 101 (2007) 182-200
40. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29 (2001) e45
41. Properzi F., Asher R.A., and Fawcett J.W. Chondroitin sulphate proteoglycans in the central nervous system: changes and synthesis after injury. Biochem. Soc. Trans. 31 (2003) 335-336
42. Qiu J., Cai D., Dai H., McAtee M., Hoffman P.N., Bregman B.S., and Filbin M.T. Spinal axon regeneration induced by elevation of cyclic AMP. Neuron 34 (2002) 895-903
43. Rhodes K.E., Raivich G., and Fawcett J.W. The injury response of oligodendrocyte precursor cells is induced by platelets, macrophages and inflammation-associated cytokines. Neuroscience 140 (2006) 87-100
44. Sandvig A., Berry M., Barrett L.B., Butt A., and Logan A. Myelin-, reactive glia-, and scar-derived CNS axon growth inhibitors: expression, receptor signaling, and correlation with axon regeneration. Glia 46 (2004) 225-251
45. Schnell L., Fearn S., Klassen H., Schwab M.E., and Perry V.H. Acute inflammatory responses to mechanical lesions in the CNS: differences between brain and spinal cord. Eur. J. Neurosci. 11 (1999) 3648-3658
46. Smith G.M., and Strunz C. Growth factor and cytokine regulation of chondroitin sulfate proteoglycans by astrocytes. Glia 52 (2005) 209-218
47. Souza-Costa D.C., Figueiredo-Lopes L., Alves-Filho J.C., Semprini M.C., Gerlach R.F., Cunha F.Q., and Tanus-Santos J.E. Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9. Crit. Care Med. 35 (2007) 239-245
48. Tang X., Davies J.E., and Davies S.J. Changes in distribution, cell associations, and protein expression levels of NG2, neurocan, phosphacan, brevican, versican V2, and tenascin-C during acute to chronic maturation of spinal cord scar tissue. J. Neurosci. Res. 71 (2003) 427-444
49. Vincent T.S., Wulfert E., and Merler E. Inhibition of growth factor signaling pathways by lovastatin. Biochem. Biophys. Res. Commun. 180 (1991) 1284-1289
50. Vollmer T., Key L., Durkalski V., Tyor W., Corboy J., Markovic-Plese S., Preiningerova J., Rizzo M., and Singh I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363 (2004) 1607-1608
51. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol. Sci. 23 (2002) 482-486
52. Wu X., Yoo S., and Wrathall J.R. Real-time quantitative PCR analysis of temporal-spatial alterations in gene expression after spinal cord contusion. J. Neurochem. 93 (2005) 943-952
53. Ye P., Sheng L., Zhang C., and Liu Y. Atorvastatin attenuating down-regulation of peroxisome proliferator-activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo. J. Pharm. Pharm. Sci. 9 (2006) 365-375